I hereby certify that this correspondence being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to "Commissioner for Patents, Washington, DC 20231" on

Atty Dkt No. 0300-0014 PATENT

addressed to commissioner for Patents, washington, DC 20231 on the patents of Patents, washington, DC 20231 on Signature

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE RECEIVED

In Re Application of:

Steven E. CWIRLA et al.

Group Art Unit: 1634

TECH CENTER 1600/2900

SEP 26 2002

Serial No.: 09/620,091

Filing Date: July 20, 2000

Examiner: Bradley L. SISSON

Title: COMPOUNDS HAVING AFFINITY FOR THE GRANULOCYTE-COLONY STIMULATING FACTOR RECEPTOR (G-CSFR) AND ASSOCIATED USES

AMENDMENT TRANSMITTAL LETTER

Commissioner for Patents Washington, DC 20231

Sir:


CHADEN

Transmitted herewith for filing is an amendment in the above patent application in response to the Office Communication mailed August 23, 2002, Paper No. 14 and the Office Action mailed on March 28, 2002.

Also enclosed: Return Post Card.

No additional amendment fee is required.

| No. of Claims After | r | | Most Claims Previously Paid | | Extra Claims | | | | Additional Fee |
|---|-----|--|--------------------------------|---|-----------------|---------------|------|---|----------------|
| A. Total Claims | 113 | | 116 | = | 0 | X | \$18 | = | 0.00 |
| B. Ind. Claims | 16 | | 16 | = | 0 | $\frac{x}{x}$ | \$84 | = | 0.00 |
| C. If amended to contain multiple dependent claims, add \$280 \$280 | | | | | | | | = | 0.00 |
| D. Total Amendment Fee (Total of A, B & C) | | | | | | | | = | 0.00 |
| E. If small entity, 50% reduction of Total Amendment Fee (50% of D) | | | | | | | | = | 0.00 |
| F. Total Amendment Fee (D minus E) | | | | | | | | = | 0.00 |
| 1. Total Michael Co (2 Mills 2) | | | | | | | | L | |



The Commissioner is hereby authorized to charge any fees under 37 CFR §§ 1.16, 1.17 and 1.21 which may be required by this paper, or to credit any overpayment, to Deposit Account No. 18-0580. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

By:

Shelley **b**. Eberle

Registration No. 31,411

REED & ASSOCIATES 800 Menlo Avenue, Suite 210 Menlo Park, California 94025 (650) 330-0900 Telephone (650) 330-0980 Facsimile

F:\Document\0300\0014\2d Amendment Transmittal.DOC





IN THE UNLES STATES PATENT AND TRADEMARK OFFICE RECEIVED

In Re Application of:

Steven E. Cwirla et al.

Serial No.: 09/620,091

Group Art Unit: 1634

TECH CENTER 1600/2900

SEP 2 6 2002

Filing Date: July 20, 2000

Examiner: Bradley L. SISSON

Title: COMPOUNDS HAVING AFFINITY FOR THE GRANULOCYTE-COLONY

STIMULATING FACTOR RECEPTOR (G-CSFR) AND ASSOCIATED USES

SECOND AMENDMENT UNDER 37 C.F.R. §1.111

Commissioner for Patents Washington, DC 20231

Sir:

This is in response to the Office Communication mailed on August 23, 2002, Paper No. 14, as well as to the Office Action mailed on March 28, 2002. As this response is being filed within the one-month date from the mailing date of the Communication, no extension of time is necessary. Applicants respectfully request entry of the following amendments and reconsideration of the application in light of the following amendments and remarks.

AMENDMENTS

IN THE CLAIMS

Claim 74 (TWICE AMENDED).

A compound comprising a peptide chain approximately 12 to 40 amino acids in length that binds to G-CSFR and displaces or prevents the binding of G-CSF at the G-CSFR, and contains a sequence of amino acids having the formula

LLDICELKLQECARRCN (SEQ ID NO: 208)

CANCEL Claims 85-87.

Claim 89 (REITERATED).

The compound of claim 74, containing a disulfide bond.